Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov ID: NCT02284425

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02284425. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of REGN1193 in patients with Type 2 Diabetes Mellitus.

Study identification

NCT ID: NCT02284425
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Regeneron Pharmaceuticals; Industry
Enrollment: 72 participants

Conditions and interventions

Conditions

Diabetes Mellitus, Type 2

Interventions

REGN1193 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 25 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2014 (Type not available)
Primary completion: Dec 2015 (Actual)
Completion: Dec 2015 (Actual)
Last update posted: May 12, 2016

2014 – 2015

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Not listed	Miami	Florida	—	—
Not listed	Atlanta	Georgia	—	—
Not listed	Knoxville	Tennessee	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02284425, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 12, 2016 · Synced Nov 15, 2026